Antibody-enabled blood stem cell transplantation
Hematopoietic stem cell transplantation (HSCT) is a powerful intervention to cure life-threatening diseases of the blood and immune system, such as acute myeloid leukemia (AML). To transplant blood stem cells, the patient’s diseased blood is removed to make room for donor stem cells and to ensure engraftment and regeneration of the donor system in the patient’s body. This first step of blood removal in a transplant is called the “conditioning phase.” Today, the conditioning phase requires intensive chemotherapy and, in some cases, radiation, which both have severe side effects that may prevent elderly and frail patients from receiving a transplant.
During their time at Wyss Zurich, the ATLyphe team, under the project name Phire, developed a novel bispecific T-cell engaging antibody with the aim to try and transform current hematopoietic stem cell transplantation practice into an immunologic precision-medicine approach.
The startup ATLYphe AG ceased operations and liquidated in the spring of 2025, returning all developments to ETH and UZH.
Faculty Mentor
